전립선암 방사선 치료 시장 - 규모, 점유율, 성장률, 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of prostate cancer radiation therapeutics Market

The global prostate cancer radiation therapeutics market is positioned for strong expansion, supported by rising disease prevalence, growing adoption of targeted radiopharmaceuticals, and continuous advancements in nuclear medicine. According to the 2025 report year data, the market was valued at USD 2.58 billion in 2025 and is projected to reach USD 3.36 billion in 2026. Over the long term, the market is forecast to grow substantially and attain USD 24.28 billion by 2034, reflecting the increasing clinical reliance on precision radiation therapies for prostate cancer management.

The growth outlook is primarily driven by the escalating global burden of prostate cancer. In 2022, approximately 1,467,854 new prostate cancer cases were recorded worldwide, highlighting the expanding patient pool requiring advanced therapeutic interventions. Radiation therapeutics, which utilize targeted radioisotopes to destroy cancer cells while minimizing damage to healthy tissues, are increasingly preferred over conventional radiation techniques due to their improved safety and treatment precision.

Market Overview and Key Metrics

From a regional standpoint, North America dominated the prostate cancer radiation therapeutics market in 2025 with a market share of 62.37%, translating to a regional market size of USD 1.61 billion. This dominance is supported by advanced healthcare infrastructure, strong reimbursement frameworks, and high awareness levels regarding early cancer diagnosis and treatment. The United States remains the largest contributor within the region due to extensive research activities, rapid regulatory approvals, and widespread access to innovative radiopharmaceutical therapies.

Europe holds the second-largest share of the market, supported by structured cancer awareness initiatives such as annual Movember campaigns and rising adoption of targeted therapies. Meanwhile, Asia Pacific is projected to be the fastest-growing region, driven by a rapidly aging population, increasing prostate cancer incidence, and expanding oncology research programs across countries such as Australia, China, and Japan.

Market Dynamics

Market Drivers

A key growth driver is the expanding geriatric population. Prostate cancer is most commonly diagnosed in men aged 65 years and above, accounting for approximately 60.0% of total diagnosed cases in 2023. Increased life expectancy, improved screening programs, and supportive reimbursement policies are collectively contributing to higher treatment uptake and sustained market growth.

Market Restraints

Despite its promising outlook, the market faces challenges due to the high cost of radiation therapeutics. For example, a single dose of Lutetium-177-based therapy can cost over USD 50,000, which limits accessibility in cost-sensitive regions. Additionally, the lack of specialized nuclear medicine infrastructure and complex regulatory requirements in developing economies continue to restrict market penetration.

Market Opportunities

Strategic collaborations for radioisotope supply represent a major opportunity area. Partnerships between pharmaceutical companies and isotope manufacturers are improving supply chain stability and accelerating clinical development of next-generation radiopharmaceuticals. Such collaborations are expected to support long-term market scalability and innovation.

Market Trends

One of the most significant trends shaping the market is the expansion of theranostics, which integrates diagnostic imaging with targeted therapy. This personalized treatment approach allows clinicians to identify suitable patients using molecular imaging before administering radioligand therapies, improving treatment outcomes and reducing adverse effects. Increasing investments in theranostic pipelines by global players underscore its growing importance in prostate cancer care.

Segmentation Insights

By Radioisotope

The Lutetium-177 segment dominated the market due to multiple regulatory approvals and strong clinical efficacy. Products such as Pluvicto have strengthened this segment's position. Radium-223 continues to show steady adoption, while other emerging radioisotopes are gaining traction through ongoing research collaborations.

By Type

The metastatic castration-resistant prostate cancer (mCRPC) segment accounts for the largest market share, driven by higher disease severity and greater demand for advanced targeted treatments. The non-metastatic segment is also expanding as companies increasingly focus on early-stage intervention.

By End User

Hospitals held the leading share in 2025 due to their advanced radiotherapy infrastructure and skilled oncology professionals. Specialty clinics are gaining momentum as patients seek focused and personalized cancer care.

Competitive Landscape

The global prostate cancer radiation therapeutics market is highly consolidated. Leading players such as Novartis AG and Bayer AG account for a significant share, supported by approved products and strong R&D pipelines. Other notable participants include Telix Pharmaceuticals, Lantheus Holdings, Clarity Pharmaceuticals, Radiopharm Theranostics, and Ariceum Therapeutics, all of which are actively investing in next-generation radiopharmaceutical development.

Report Scope

The 2025 report provides a detailed analysis of market size and value for 2025, 2026, and 2034, along with in-depth insights into market dynamics, segmentation, regional outlook, competitive landscape, and key industry developments. The coverage emphasizes regulatory approvals, product launches, collaborations, and the evolving role of precision radiation therapies in prostate cancer treatment, offering a comprehensive view of the market's future trajectory.

Conclusion

The prostate cancer radiation therapeutics market is entering a phase of accelerated transformation, supported by strong clinical demand, rapid technological advancement, and expanding acceptance of targeted radiopharmaceuticals. With the market valued at USD 2.58 billion in 2025, projected to reach USD 3.36 billion in 2026, and forecast to surge to USD 24.28 billion by 2034, the outlook clearly reflects the growing clinical reliance on precision radiation therapies. High disease prevalence, particularly among men aged 65 years and above, and the increasing shift toward personalized medicine are reinforcing long-term demand. North America's dominance, holding 62.37% market share in 2025, highlights the importance of advanced healthcare infrastructure and favorable reimbursement environments, while Asia Pacific's rapid expansion signals emerging opportunities. Despite challenges related to high treatment costs and regulatory complexity, ongoing collaborations, theranostics adoption, and robust R&D pipelines from leading companies are expected to sustain strong momentum. Overall, the market is well-positioned for sustained expansion through 2034, driven by innovation, precision oncology trends, and rising global prostate cancer burden.

Segmentation By Radioisotope, Type, End-User, and Region

By Radioisotope * Radium-223

• Lutetium-177
• Others

By Type * Metastatic Castration-Resistant Prostate Cancer

• Non-Metastatic Castration-Resistant Prostate Cancer

By End-User * Hospitals

• Specialty Clinics
• Others

By Region * North America (By Radioisotopes, Type, End-User, and Country)

• U.S.
• Canada
• Europe (By Radioisotopes, Type, End-User, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific (By Radioisotopes, Type, End-User, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Rest of the World (By Radioisotopes, Type, and End-User)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2025
• 4.2. Pipeline Analysis, by Key Players
• 4.3. Overview of Alternative Therapies
• 4.4. New Product Launches, by Key Players
• 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• 4.6. Impact of COVID-19 on the Market

5. Global Prostate Cancer Radiation Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Radioisotope
  • 5.1.1. Radium-223
  • 5.1.2. Lutetium-177
  • 5.1.3. Others
• 5.2. Market Analysis, Insights and Forecast - By Type
  • 5.2.1. Metastatic Castration-Resistant Prostate Cancer
  • 5.2.2. Non-Metastatic Castration-Resistant Prostate Cancer
• 5.3. Market Analysis, Insights and Forecast - By End-user
  • 5.3.1. Hospitals
  • 5.3.2. Specialty Clinics
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Rest of the World

6. North America Prostate Cancer Radiation Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Radioisotope
  • 6.1.1. Radium-223
  • 6.1.2. Lutetium-177
  • 6.1.3. Others
• 6.2. Market Analysis, Insights and Forecast - By Type
  • 6.2.1. Metastatic Castration-Resistant Prostate Cancer
  • 6.2.2. Non-Metastatic Castration-Resistant Prostate Cancer
• 6.3. Market Analysis, Insights and Forecast - By End-user
  • 6.3.1. Hospitals
  • 6.3.2. Specialty Clinics
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Prostate Cancer Radiation Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Radioisotope
  • 7.1.1. Radium-223
  • 7.1.2. Lutetium-177
  • 7.1.3. Others
• 7.2. Market Analysis, Insights and Forecast - By Type
  • 7.2.1. Metastatic Castration-Resistant Prostate Cancer
  • 7.2.2. Non-Metastatic Castration-Resistant Prostate Cancer
• 7.3. Market Analysis, Insights and Forecast - By End-user
  • 7.3.1. Hospitals
  • 7.3.2. Specialty Clinics
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.4.1. Germany
  • 7.4.2. U.K.
  • 7.4.3. France
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Prostate Cancer Radiation Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Radioisotope
  • 8.1.1. Radium-223
  • 8.1.2. Lutetium-177
  • 8.1.3. Others
• 8.2. Market Analysis, Insights and Forecast - By Type
  • 8.2.1. Metastatic Castration-Resistant Prostate Cancer
  • 8.2.2. Non-Metastatic Castration-Resistant Prostate Cancer
• 8.3. Market Analysis, Insights and Forecast - By End-user
  • 8.3.1. Hospitals
  • 8.3.2. Specialty Clinics
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.4.1. China
  • 8.4.2. Japan
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Rest of the World Prostate Cancer Radiation Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Radioisotope
  • 9.1.1. Radium-223
  • 9.1.2. Lutetium-177
  • 9.1.3. Others
• 9.2. Market Analysis, Insights and Forecast - By Type
  • 9.2.1. Metastatic Castration-Resistant Prostate Cancer
  • 9.2.2. Non-Metastatic Castration-Resistant Prostate Cancer
• 9.3. Market Analysis, Insights and Forecast - By End-user
  • 9.3.1. Hospitals
  • 9.3.2. Specialty Clinics
  • 9.3.3. Others

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2025)
• 10.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
  • 10.2.1. Novartis AG
  • 10.2.2. Bayer AG
  • 10.2.3. Telix Pharmaceuticals Limited
  • 10.2.4. Ariceum Therapeutics
  • 10.2.5. Radiopharm Theranostics Limited
  • 10.2.6. Lantheus Holdings, Inc.
  • 10.2.7. Clarity Pharmaceuticals